Weijie Wu

Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment.

Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment.

Journal: Molecular cancer

Published: July 04, 2026

A Reproducible MRI-Based Quantitative Feature for Differentiating Dysplastic Nodules from Hepatocellular Carcinoma: A Multicenter Retrospective Study.

A Reproducible MRI-Based Quantitative Feature for Differentiating Dysplastic Nodules from Hepatocellular Carcinoma: A Multicenter Retrospective Study.

Journal: Journal of hepatocellular carcinoma

Published: March 13, 2026

Efficacy and safety of PD-1 inhibitors for advanced intrahepatic cholangiocarcinoma with or without MAFLD.

Efficacy and safety of PD-1 inhibitors for advanced intrahepatic cholangiocarcinoma with or without MAFLD.

Journal: iLIVER

Published: March 20, 2025

Rehabilitative effects of Transcutaneous Electric Nerve Stimulation on limb function in stroke patients: a systematic review and meta-analysis.

Rehabilitative effects of Transcutaneous Electric Nerve Stimulation on limb function in stroke patients: a systematic review and meta-analysis.

Journal: Disability and rehabilitation

Published: February 11, 2025

Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment.

Correction: YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment.

Journal: Molecular cancer

Published: January 31, 2025

Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study.

Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study.

Journal: Frontiers in immunology

Published: September 11, 2024

The CRAFITY score emerges as a paramount prognostic indicator in hepatocellular carcinoma patients received Lenvatinib and Pembrolizumab.

The CRAFITY score emerges as a paramount prognostic indicator in hepatocellular carcinoma patients received Lenvatinib and Pembrolizumab.

Journal: Frontiers in immunology

Published: August 01, 2024

YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment.

YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment.

Journal: Molecular cancer

Published: April 17, 2024

Efficacy of additional locoregional therapy based on systemic therapy after intrahepatic progression for BCLC stage B/C hepatocellular carcinoma: A real-world study.

Efficacy of additional locoregional therapy based on systemic therapy after intrahepatic progression for BCLC stage B/C hepatocellular carcinoma: A real-world study.

Journal: International immunopharmacology

Published: October 13, 2023

Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma.

Comparable Clinical Outcomes Between Transarterial Chemoembolization or Hepatic Arterial Infusion Chemotherapy Combined with Tyrosine Kinase Inhibitors and PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma.

Journal: Journal of hepatocellular carcinoma

Published: September 12, 2023

Acupuncture for cognitive impairment after stroke: A systematic review and meta-analysis.

Acupuncture for cognitive impairment after stroke: A systematic review and meta-analysis.

Journal: Heliyon

Published: June 13, 2023

Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma.

Comparison of hepatic arterial infusion chemotherapy with mFOLFOX vs. first-line systemic chemotherapy in patients with unresectable intrahepatic cholangiocarcinoma.

Journal: Frontiers in pharmacology

Published: June 04, 2023

Showing 1-12 of 16

Last Updated: 09/26/2026